



**Alexandra (Sandra) Glucksmann, Ph.D.**, is currently Senior Vice President of Research and Business Operations at Cerulean Pharma, which she joined in October 2006 at its founding. Cerulean Pharma is developing a proprietary nanoparticle technology designed to improve the safety and efficacy of marketed and development-stage drugs. Prior to joining Cerulean, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions of increasing responsibility, ultimately becoming vice president of all platform technology groups before moving into a senior role in strategic program management and operations, where she worked closely with the CEO and led company-wide process improvement initiatives and participated in business development and M&A efforts. During her tenure at Millennium, Alexandra was critical to helping Millennium evolve from a genomics research-focused organization to a fully integrated pharmaceuticals company with products on the market. Her division played an integral role in the numerous Millennium-large pharma collaborations, which raised over \$1.8 billion in funding for the company. She serves on the Board of Directors of Taconic Farms and is the Chair of the Board of Women Entrepreneurs in Science and Technology. She is also a member of Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics. Sandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.